MX2018011512A - Uso de insulina para promover el vaciamiento gástrico. - Google Patents
Uso de insulina para promover el vaciamiento gástrico.Info
- Publication number
- MX2018011512A MX2018011512A MX2018011512A MX2018011512A MX2018011512A MX 2018011512 A MX2018011512 A MX 2018011512A MX 2018011512 A MX2018011512 A MX 2018011512A MX 2018011512 A MX2018011512 A MX 2018011512A MX 2018011512 A MX2018011512 A MX 2018011512A
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- gastric emptying
- promoting gastric
- promoting
- composition
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 230000030136 gastric emptying Effects 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- 230000001737 promoting effect Effects 0.000 title abstract 3
- 208000012895 Gastric disease Diseases 0.000 abstract 1
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación proporciona medios y métodos para promover el vaciamiento gástrico. En particular, la presente divulgación proporciona el uso de insulina o una composición que comprende la misma para promover el vaciamiento gástrico y para tratar trastornos gástricos, particularmente trastornos caracterizados por un vaciamiento gástrico retardado. La insulina o la composición que la comprende deben ser administradas por vía enteral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312473P | 2016-03-24 | 2016-03-24 | |
| PCT/US2017/024053 WO2017165789A1 (en) | 2016-03-24 | 2017-03-24 | Use of insulin for promoting gastric emptying |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011512A true MX2018011512A (es) | 2019-02-07 |
Family
ID=59900798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011512A MX2018011512A (es) | 2016-03-24 | 2017-03-24 | Uso de insulina para promover el vaciamiento gástrico. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10046032B2 (es) |
| EP (1) | EP3432861B1 (es) |
| JP (1) | JP7102347B2 (es) |
| KR (1) | KR20180123114A (es) |
| CN (1) | CN109152733A (es) |
| AR (1) | AR108753A1 (es) |
| AU (1) | AU2017237164A1 (es) |
| BR (1) | BR112018069444A2 (es) |
| CA (1) | CA3018215C (es) |
| ES (1) | ES2957891T3 (es) |
| HR (1) | HRP20230972T1 (es) |
| HU (1) | HUE062950T2 (es) |
| IL (1) | IL261898A (es) |
| MX (1) | MX2018011512A (es) |
| PL (1) | PL3432861T3 (es) |
| RS (1) | RS64623B1 (es) |
| RU (1) | RU2018133604A (es) |
| SG (1) | SG11201808154XA (es) |
| SM (1) | SMT202300323T1 (es) |
| WO (1) | WO2017165789A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10046032B2 (en) | 2016-03-24 | 2018-08-14 | Nutrinia, Ltd. | Use of insulin for promoting gastric emptying |
| BR112023020961A2 (pt) * | 2021-04-11 | 2023-12-12 | Elgan Pharma Ltd | Formulações de insulina e métodos para usar a mesma em bebês prematuros |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE106242T1 (de) | 1986-08-28 | 1994-06-15 | Enzacor Pty Ltd | Mikrogranuläre zubereitung zur verabreichung biologisch aktiver stoffe in den eingeweideregionen von tieren. |
| US5356625A (en) | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
| FR2606597B1 (fr) | 1986-11-17 | 1989-01-27 | Rhone Poulenc Sante | Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation |
| US4944944A (en) | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
| US5013569A (en) | 1990-05-21 | 1991-05-07 | Century Laboratories, Inc. | Infant formula |
| US5418010A (en) | 1990-10-05 | 1995-05-23 | Griffith Laboratories Worldwide, Inc. | Microencapsulation process |
| DE4100920A1 (de) | 1991-01-15 | 1992-07-16 | Degussa | Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer |
| US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| US5360614A (en) | 1993-04-26 | 1994-11-01 | The Estee Corporation | Method of controlling the release of carbohydrates by encapsulation and composition therefor |
| US5405637A (en) | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
| US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
| ATE207312T1 (de) | 1995-06-29 | 2001-11-15 | Nestle Sa | Verfahren zur verkapselung eines kernmaterials mit einem polymer durch hochdruckbehandlung |
| JPH10155428A (ja) | 1996-12-04 | 1998-06-16 | Shida Kanzume Kk | 毛づや改善剤及び毛づやの改善方法、並びに健康食品 |
| CN1660065A (zh) | 1997-03-27 | 2005-08-31 | 布里斯托尔-迈尔斯斯奎布公司 | 二十二碳六烯酸和花生四烯酸促进不足月婴儿生长的用途 |
| JPH119196A (ja) | 1997-06-24 | 1999-01-19 | Meiji Seika Kaisha Ltd | キトサンによる家畜の損耗防止の方法 |
| KR100551221B1 (ko) | 1997-09-09 | 2006-02-10 | 리오트로픽테라피우틱스 인코퍼레이션 | 코팅된 입자, 그 제조방법 및 그 사용방법 |
| US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| US6399090B1 (en) | 1998-06-05 | 2002-06-04 | Insotech Ltd. | Insulin supplemented infant formula |
| WO1999062558A1 (en) | 1998-06-05 | 1999-12-09 | Technion Research And Development Foundation Ltd. | Insulin supplemented infant formula |
| JP2000050793A (ja) * | 1998-08-07 | 2000-02-22 | Meiji Milk Prod Co Ltd | 人工乳組成物 |
| JP2000116320A (ja) | 1998-10-13 | 2000-04-25 | Bingu Gure:Kk | 乳酸菌カプセル入りヨーグルト及びその製造方法 |
| GB2345836A (en) | 1999-01-25 | 2000-07-26 | Charleville Res | Animal milk replacer |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6548043B1 (en) | 1999-08-03 | 2003-04-15 | Metabolic Solutions, Inc. | Measurement of gastric emptying |
| WO2001078781A2 (en) * | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| ES2262667T3 (es) | 2000-05-25 | 2006-12-01 | Societe Des Produits Nestle S.A. | Probioticos nuevos para aplicaciones en alimento para animales de compañia. |
| DE60018586T2 (de) | 2000-12-15 | 2006-04-06 | Quest International B.V. | Eine Feuchtigkeit- und Sauerstoff-stabile Zusammensetzung und Verfahren zur Herstellung |
| JP2002209513A (ja) | 2000-12-15 | 2002-07-30 | Bingu-Gure:Kk | 栄養成分を含有する多数のカプセル入り強化牛乳 |
| AUPR272901A0 (en) | 2001-01-25 | 2001-02-22 | Gainful Plan Limited | Method of preparing biological materials and preparations produced using same |
| CN1531399A (zh) | 2001-05-14 | 2004-09-22 | 瓦西里・彼得罗维奇・安德烈丘克 | 预防碘缺乏和优化碘代谢的生物活性食品添加剂和生物活性饲料添加剂,以及含该添加剂的食品和饲料 |
| US20050226905A1 (en) | 2001-05-22 | 2005-10-13 | Tien Canh L | Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for food protection |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US6951655B2 (en) | 2001-10-11 | 2005-10-04 | Imi Biomed, Inc. | Pro-micelle pharmaceutical compositions |
| US20030175382A1 (en) | 2002-03-14 | 2003-09-18 | Dally Vernetta L. | Heat released encapsulated yeast |
| US20030175403A1 (en) | 2002-03-14 | 2003-09-18 | Gurin Michael H. | Potentiated bioactive additives and method of use |
| EP1517981A2 (en) | 2002-07-01 | 2005-03-30 | Novozymes A/S | Stabilization of granules |
| US6835397B2 (en) | 2002-12-23 | 2004-12-28 | Balchem Corporation | Controlled release encapsulated bioactive substances |
| US8877232B2 (en) * | 2003-06-20 | 2014-11-04 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
| EP1758464A4 (en) * | 2004-05-24 | 2012-10-24 | Nutrinia Ltd | NUTRITIONAL FOOD AND SUPPLEMENT, ITS COMPOSITION, PROCESSING AND METHOD FOR ITS USE |
| US8026211B2 (en) * | 2004-06-02 | 2011-09-27 | Technion Research & Development Foundation Ltd. | Methods and formulations for increasing intestinal function |
| GB0502795D0 (en) | 2005-02-10 | 2005-03-16 | Univ Cambridge Tech | Treatment of very low birthweight (vlbw) infants |
| EP1933862B1 (en) | 2005-09-06 | 2014-03-26 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| JP2010528651A (ja) * | 2007-06-07 | 2010-08-26 | ニュートリニア リミテッド | 家禽の体重増量を向上させるための手段および方法 |
| US7943733B2 (en) | 2007-12-20 | 2011-05-17 | University Of Southern California | Spacers to increase the expression of recombinant fusion proteins |
| RU2013123053A (ru) | 2010-10-21 | 2014-11-27 | Сведиш Орфан Биовитрум Аб (Пабл) | Способ увеличения скорости роста новорожденных детей |
| EP2520298A1 (en) | 2011-05-03 | 2012-11-07 | Assistance Publique, Hopitaux De Paris | Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant |
| MX2014012671A (es) | 2012-04-18 | 2015-06-05 | Nutrinia Ltd | Mejoramiento del crecimiento de infantes. |
| WO2013179290A1 (en) | 2012-05-31 | 2013-12-05 | Nutrinia Ltd. | Insulin-containing infant formula |
| US10046032B2 (en) | 2016-03-24 | 2018-08-14 | Nutrinia, Ltd. | Use of insulin for promoting gastric emptying |
-
2017
- 2017-03-24 US US15/468,965 patent/US10046032B2/en active Active
- 2017-03-24 WO PCT/US2017/024053 patent/WO2017165789A1/en not_active Ceased
- 2017-03-24 JP JP2018549878A patent/JP7102347B2/ja active Active
- 2017-03-24 KR KR1020187029772A patent/KR20180123114A/ko not_active Ceased
- 2017-03-24 BR BR112018069444A patent/BR112018069444A2/pt not_active Application Discontinuation
- 2017-03-24 AU AU2017237164A patent/AU2017237164A1/en not_active Abandoned
- 2017-03-24 MX MX2018011512A patent/MX2018011512A/es unknown
- 2017-03-24 CN CN201780030498.8A patent/CN109152733A/zh active Pending
- 2017-03-24 CA CA3018215A patent/CA3018215C/en active Active
- 2017-03-24 SG SG11201808154XA patent/SG11201808154XA/en unknown
- 2017-03-24 RU RU2018133604A patent/RU2018133604A/ru not_active Application Discontinuation
- 2017-03-24 HU HUE17771247A patent/HUE062950T2/hu unknown
- 2017-03-24 RS RS20230856A patent/RS64623B1/sr unknown
- 2017-03-24 SM SM20230323T patent/SMT202300323T1/it unknown
- 2017-03-24 HR HRP20230972TT patent/HRP20230972T1/hr unknown
- 2017-03-24 EP EP17771247.8A patent/EP3432861B1/en active Active
- 2017-03-24 PL PL17771247.8T patent/PL3432861T3/pl unknown
- 2017-03-24 ES ES17771247T patent/ES2957891T3/es active Active
- 2017-03-27 AR ARP170100743A patent/AR108753A1/es not_active Application Discontinuation
-
2018
- 2018-09-20 IL IL261898A patent/IL261898A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS64623B1 (sr) | 2023-10-31 |
| SMT202300323T1 (it) | 2023-11-13 |
| AU2017237164A1 (en) | 2018-10-11 |
| EP3432861B1 (en) | 2023-07-12 |
| CN109152733A (zh) | 2019-01-04 |
| HUE062950T2 (hu) | 2023-12-28 |
| CA3018215C (en) | 2023-10-03 |
| KR20180123114A (ko) | 2018-11-14 |
| EP3432861A1 (en) | 2019-01-30 |
| EP3432861A4 (en) | 2019-10-23 |
| BR112018069444A2 (pt) | 2019-10-08 |
| JP7102347B2 (ja) | 2022-07-19 |
| AR108753A1 (es) | 2018-09-26 |
| WO2017165789A1 (en) | 2017-09-28 |
| IL261898A (en) | 2018-10-31 |
| US20170319663A1 (en) | 2017-11-09 |
| US10046032B2 (en) | 2018-08-14 |
| JP2019509317A (ja) | 2019-04-04 |
| SG11201808154XA (en) | 2018-10-30 |
| HRP20230972T1 (hr) | 2023-12-08 |
| NZ746622A (en) | 2024-12-20 |
| CA3018215A1 (en) | 2017-09-28 |
| RU2018133604A (ru) | 2020-04-24 |
| PL3432861T3 (pl) | 2023-12-18 |
| EP3432861C0 (en) | 2023-07-12 |
| ES2957891T3 (es) | 2024-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017002271A (es) | Composiciones y metodos para el tratamiento de trastornos neurologicos. | |
| MX2022001043A (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas. | |
| PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
| MD20170035A2 (ro) | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
| MD4801B1 (ro) | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| MX359029B (es) | Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. | |
| SG10201804034QA (en) | Methods for treating hypotension | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
| WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
| PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
| EP3549582A3 (en) | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases | |
| MX2018011512A (es) | Uso de insulina para promover el vaciamiento gástrico. | |
| PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
| PH12019501358A1 (en) | Methods of administering hepcidin |